Physiological Role and Source
The endogenous growth factor is protein-based and classified as a glycoprotein. The majority of the substance (90%) is synthesized in the peritubular cells of the kidneys, while the remaining 10% is produced by liver cells. The primary trigger for a sharp increase in endogenous erythropoietin production is tissue hypoxia. In chronic kidney disease, this natural synthesis drops significantly, creating a need for medical intervention.
Cellular Mechanism of Action
The substance aims to stimulate the production of new red blood cells:
- The active ingredient identifies and binds to high-affinity receptors (EpoR) located on the membranes of immature erythroid cells.
- Proliferation and differentiation of progenitor cells are stimulated.
- The physiological release of reticulocytes directly from the bone marrow into the bloodstream is accelerated.
Pharmacology and Indications
For therapeutic use, recombinant agents produced via genetic engineering are used as complete analogs of human erythropoietin. Key representatives of this group include epoetin alfa and epoetin beta.
These agents are administered parenterally—either subcutaneously or intravenously—with dosages calculated in IU per kilogram of body weight. The main indications include various types of anemia:
- Anemia in chronic kidney disease (CKD).
- Bone marrow disorders and malignancies.
- Chronic inflammatory conditions and HIV/AIDS.
- Anemia of prematurity in neonates.
Time Course and Safety
The therapeutic response develops gradually:
- Initial clinical results are noticeable 1–2 weeks after starting the course.
- Complete normalization of hematopoiesis parameters is observed within 8–12 weeks.
Administration requires close safety monitoring due to potential adverse effects:
- Cardiovascular system: elevated blood pressure, hypertensive crises, thrombosis, chest pain, and edema.
- Nervous system (typically secondary to blood pressure spikes or encephalopathy): severe headaches, dizziness, confusion, and seizures.